Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Pharmacyclics grants Alcon rights to Lu-Tex

Dec. 19, 1997

InSite Vision brings its once-daily glaucoma treatment to clinical trials

Dec. 8, 1997

Alcon compounds with dual antioxidant/cysteine prodrug properties

Dec. 8, 1997

Spotlight on carbonic anhydrase inhibitors for glaucoma

Nov. 25, 1997

KeraVision Ring evaluated in extended phase III trial

Nov. 21, 1997

Promising phase III results reported for KeraVision ring

Nov. 4, 1997

German launch for Xalatan

Oct. 23, 1997

Patient recruitment for verteporfin phase III trials exceeds goals

Sep. 30, 1997

Lotemax deemed approvable by FDA

Sep. 26, 1997

Angiogenesis inhibitors described by Janssen

Sep. 25, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...